San Francisco, California
London, United Kingdom
External open innovation is becoming increasingly essential to drug discovery. As academic-industry collaborations heat up, the opportunity for success lies in partnerships with common goals. Thus, it is critical to understand the desires and needs of each partner. How do we forge meaningful collaborations? When is novel science ready for translation to treatments and collaborative partnering? How can academic scientists and industry work best together?
Anthony J. Coyle, PhD will provide an overview of Pfizer's Centers for Therapeutic Innovation (CTI), the evolution to create a new biomedical ecosystem, and key attributes of the open innovation model. Learn how you can contribute and gain from this ecosystem and work collaboratively to close the gap from research discovery to clinical application, and ultimately benefit those patients who are waiting.
* Pfizer's vision for creating CTI and building a new R&D ecosystem
* Challenges and opportunities with academic-industry partnerships
* Innovative partnership opportunities with Pfizer
* New in 2013: Call for Small Molecule Proposals